ASX 300 healthcare stock Sigma halted amid rumours of blockbuster Chemist Warehouse deal

Is Chemist Warehouse finally joining the ASX?

| More on:
Two happy pharmacists standing together in a pharmacy.

Image source: Getty Images

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

The shares of ASX 300 healthcare stock Sigma Healthcare Ltd (ASX: SIG) were pushing higher on Wednesday before being slammed into a trading halt this afternoon at the pharmacy operator's request.

According to the release, the company requested the halt pending the release of a big announcement. Its request states:

The trading halt is requested pending an announcement relating to a potential material transaction and is required to ensure Sigma shares are not trading on a misinformed basis.

What's going on with Sigma shares?

The rumour on the street is that Sigma shares have been halted today while it prepares to announce a reverse listing deal that will see pharmacy giant Chemist Warehouse listed on the Australian share market at long last.

According to the SMH, sources have told the media outlet that the two parties are close to agreeing a deal that would see Chemist Warehouse take board control and a majority ownership of Sigma.

The sources also claim that the deal could result in Sigma seeking to raise $400 million from investors to shore up its balance sheet and provide more liquidity.

Over at the AFR, it is reporting that the company will be seeking to raise $350 million to support the reverse listing of the privately owned Chemist Warehouse business.

Neither company has confirmed the reports yet. However, ASX 300 healthcare stock Sigma intends to release an announcement in relation to the "material transaction" before the market open on Friday.

So far, this news hasn't had an impact on Wesfarmers Ltd (ASX: WES) shares this afternoon. They have continued to rise despite the rumours. The conglomerate acquired Priceline-owner Australian Pharmaceutical Industries last year for almost $800 million.

Motley Fool contributor James Mickleboro has no position in any of the stocks mentioned. The Motley Fool Australia's parent company Motley Fool Holdings Inc. has positions in and has recommended Wesfarmers. The Motley Fool Australia has positions in and has recommended Wesfarmers. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

More on Healthcare Shares

A man in a white coat holds a laptop in one hand and his head in the other, it's bad news.
Healthcare Shares

Why is this ASX 200 pharmaceuticals stock crashing 15% today?

Investors haven't responded positively to a sales update.

Read more »

A little girl with red hair runs excitedly with a rocket strapped to her back, trying to launch.
Share Gainers

This small-cap ASX stock just rocketed 39%. What's doing?

A stock no one has heard of is lighting up trading screens on Wednesday. You might hear this name more…

Read more »

Research, collaboration and doctors working digital tablet, analysis and discussion of innovation cancer treatment. Healthcare, teamwork and planning by experts sharing idea and strategy for surgery.
Healthcare Shares

Has the CSL share price got further to fall?

ASX experts weigh in on what's next for CSL.

Read more »

Shot of a young scientist using a laptop while conducting research in a laboratory.
Healthcare Shares

2 popular ASX 200 healthcare shares tanking on earnings updates

Let's check out the earnings reports from these two ASX 200 healthcare shares today.

Read more »

Stethoscope with a piggy bank and hundred dollar notes.
Healthcare Shares

Hoping to bag the record Medibank dividend? Here's what you need to do

Time is running out if you'd like to bank the ASX 200 healthcare stock's largest-ever dividend.

Read more »

A woman with a sad face looks to be receiving bad news on her phone as she holds it in her hands and looks down at it.
Earnings Results

Nanosonics share price crashes 14% on first-half profit crunch

Investors haven't responded positively to the release of the company's half-year results.

Read more »

Three excited business people cheer around a laptop in the office
Healthcare Shares

Here's why ResMed shares can jump a further 20%

Investors have done very well from this stock recently. The good news is that analysts expect the trend to continue.

Read more »

Shot of a young scientist using a digital tablet while working in a lab.
Share Gainers

If you'd put $20,000 in this ASX healthcare stock during COVID-19, you'd have $257,000 now

You could have become filthy rich in just 4 years. Just think about that.

Read more »